The first step involves insurance verification to ensure your coverage
Semaglutide vs Liraglutide: The Basics While both medications mimic the GLP-1 hormone, they are manufactured differently, prescribed under different brand names, and administered on different schedules
Semaglutide Weekly Injection Active Ingredient in Ozempic and Wegovy 15% Body Weight Reduction GLP-1 Receptor Agonist FDA Approved for Type 2 Diabetes (2017) and Weight Loss (2021) Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain Tirzepatide Weekly Injection Active Ingredient in Mounjaro 20% Body Weight reduction Dual GLP-1 and GIP Receptor Agonist FDA Approved for Type 2 Diabetes (2022) and on Fast-track for Weight Loss Approval in 2023 Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain These injections are GLP-1 medications that have been FDA-approved for Type 2 diabetes because of their ability to lower blood sugar and raise insulin levels
Central Drugs Standard Control Organization, Indias top drug authority, did not respond to an emailed request for comment
I covered the trial and why this form of training behaves differently here
[DOI] [PubMed] [Google Scholar] 110.Haneke E, Baran R
